Kristina (Kris) Bieker-Brady, PhD represents private and public side biotech, pharmaceutical and medical device companies, with a focus on portfolio development, financings, public offerings, mergers and strategic partnerships. Kris is highly skilled in managing multiple facets of clients’ intellectual property portfolio through the majority of the company’s life cycle. Particularly, she works to build and preserve layered exclusivity profiles that are structured to peak in strength during the critical periods of a product’s branded commercial sales life.
Kris also advises clients on other matters relating to patent prosecution, including patentability, non-infringement and invalidity opinions, licensing, joint development agreements and patent enforcement. Additionally, she performs IP due diligence on potential investments for some of the top venture capital firms in the world. Many of her relationships with venture capital firms and serial entrepreneurs span a period of more than 15 years.
Kris’ experience encompasses cellular immunotherapies; gene therapy; nano and viral systems for oncolytic, gene therapy and vaccine indications; preventative medicine; treatments for devastating neurological and other tissue injuries; treatments—and more critically cures—for developmental and progressive neurological diseases such as autism, ALS and Alzheimer’s.
Prior to joining McDermott, Kris spent 22 years as a co-founder and eight years as a managing partner of an IP law firm dedicated to life sciences patent prosecution.
During her academic career, Kris conducted cell biology, genetics and neurobiology research using molecular biology and biochemistry techniques. Select first-author research and review articles have been published in Cell, EMBO Journal, Proceedings of the National Academy of Sciences, Genomics and Trends in Genetics.
*Matter handled prior to joining McDermott.